RCM
STOK icon

RA Capital Management’s Stoke Therapeutics STOK Stock Holding History

RA Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,119,963
Closed -$26.7M – 74
2020
Q2 		$26.7M Hold
1,119,963
– – 0.52% 36
2020
Q1 		$25.6M Hold
1,119,963
– – 0.81% 33
2019
Q4 		$31.7M Hold
1,119,963
– – 0.96% 23
2019
Q3 		$24.1M Hold
1,119,963
– – 1.43% 18
2019
Q2 		$32.7M Buy
+1,119,963
New +$30.1M 1.75% 16

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RA Capital Management's STOK Position: Q3 2020 in Review

RA Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2020, closing a stake of 1,119,963 shares — an estimated $26.7M sold.

RA Capital Management first reported a position in STOK in Q2 2019 and held it in 5 quarters. The position peaked at $32.7M in Q2 2019. 88 funds tracked by Wall St. Rank hold STOK as of Q3 2020.

  • RA Capital Management reported no remaining Stoke Therapeutics position as of Q3 2020 after selling out during the quarter.
  • RA Capital Management sold 1,119,963 Stoke Therapeutics shares in Q3 2020, an estimated $26.7M.
  • RA Capital Management first reported a position in Stoke Therapeutics in Q2 2019 and held it in 5 quarters.
  • RA Capital Management's Stoke Therapeutics position peaked at $32.7M in Q2 2019.
  • 88 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2020.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.